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The histone lysine demethylase KDM4A/JMJD2A
has been implicated in prostate carcinogenesis
through its role in transcriptional regulation. Here,
we describe KDM4A as a E2F1 coactivator and
demonstrate a functional role for the E2F1-KDM4A
complex in the control of tumor metabolism.
KDM4A associates with E2F1 on target gene pro-
moters and enhances E2F1 chromatin binding and
transcriptional activity, thereby modulating the tran-
scriptional profile essential for cancer cell prolifera-
tion and survival. The pyruvate dehydrogenase ki-
nases (PDKs) PDK1 and PDK3 are direct targets of
KDM4A and E2F1 and modulate the switch between
glycolytic metabolism and mitochondrial oxidation.
Downregulation of KDM4A leads to elevated ac-
tivity of pyruvate dehydrogenase and mitochondrial
oxidation, resulting in excessive accumulation of
reactive oxygen species. The altered metabolic phe-
notypes can be partially rescued by ectopic ex-
pression of PDK1 and PDK3, indicating a KDM4A-
dependent tumor metabolic regulation via PDK.
Our results suggest that KDM4A is a key regulator
of tumor metabolism and a potential therapeutic
target for prostate cancer.INTRODUCTION
Histone lysine methylation is generally involved in transcriptional
regulation, and histone lysine demethylase (KDM) is the enzyme
that specifically catalyzes the removal of methyl groups from
lysine residues. Since the discovery of the first KDM, many
KDMs have been reported to be genetically altered or aberrantly
expressed in awide spectrum of cancer types (Cloos et al., 2006;3016 Cell Reports 16, 3016–3027, September 13, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://Varier and Timmers, 2011). Thus, targeting KDMs has been
increasingly recognized as an anticancer therapeutic strategy
(Højfeldt et al., 2013; McGrath and Trojer, 2015). KDM4A (or
JMJD2A) is Jumonji (JmjC)-domain-containing demethylase
and belongs to the KDM4 family that specifically demethylates
H3K9me3/2 and H3K36me3/2, with the highest affinity toward
H3K9me3 (Couture et al., 2007; Hillringhaus et al., 2011; Whets-
tine et al., 2006). The most characterized role of H3K9me3 is in
the establishment of heterochromatin; while its existence in
euchromatin and active loci represses transcription, is important
for gene silencing. Like other KDM4 family members, KDM4A is
recognized as a transcriptional regulator for gene activation or
repression. When forming complexes with androgen receptor
(AR) or estrogen receptor (ER), KDM4A stimulates their tran-
scriptional activity and induces the expression of target genes
that are important for proliferation in prostate and breast cancer
(Berry et al., 2012; Shin and Janknecht, 2007). On the other hand,
KDM4A is also reported as a transcriptional repressor when
binding with repressive factors such as nuclear receptor core-
pressor (N-CoR) and histone deacetylases (Gray et al., 2005;
Zhang et al., 2005). In addition to transcription, KDM4A is also
implicated in several other molecular processes, such as DNA
damage response (Mallette et al., 2012), DNA replication (Black
et al., 2010), site-specific copy gain (Black et al., 2013), and
translation (Van Rechem et al., 2015). With such diverse roles
in cellular processes, it is not surprising that there have
been numerous reports about the association of deregulated
KDM4A with cancer, including prostate cancers (Chu et al.,
2014; Duan et al., 2015; Kim et al., 2016; Shin and Janknecht,
2007). Previously, we reported a small molecule, NSC636819,
that exhibits potent inhibition of KDM4A and KDM4B (Chu
et al., 2014). We showed that KDM4A and 4B are overexpressed
in prostate cancers and that both pharmacological and genetic
inactivation of these KDMs strongly inhibits the cancer growth.
Consistently, a recent report identifying another potent inhibitor
for KDM4 (Duan et al., 2015) also demonstrated that inhibiting
both KDM4A and 4B is a promising therapeutic strategy for
castration-resistant prostate cancer (CRPC).uthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
E2F1 is well recognized as a partner of retinoblastoma protein
(Rb) and as a critical factor in growth regulation by serving as a
transcriptional activator of many cell-cycle genes. There is
strong evidence that E2F1 is involved in the development of
CRPC. For instance, E2F1 overexpression leads to the castra-
tion-resistance phenotype of LNCaP (Libertini et al., 2006), E2F
transcriptome is one of the prominent molecular signatures of
CRPC (Sharma et al., 2013), and E2F1 coordinates with AR (Ra-
mos-Montoya et al., 2014) to modulate genes involved in CRPC.
In addition to regulating cell-cycle and AR genes, E2F1 is also
involved in metabolic regulation, as evidenced by the higher
oxidative metabolism and lower glycolysis associated with
E2F1 homozygous knockout mice (Blanchet et al., 2011). The
mechanism however, remains obscure.
Recently, tumormetabolism has gained increasing attention in
cancer research. One of cancer cells’ hallmarks is the Warburg
effect, by which cancer cells heavily rely on glycolysis to obtain
energy and producemacromolecules that are required to sustain
rapid proliferation. To this end, cancer cells divert the glycolytic
metabolite pyruvate from entering mitochondria for the tricar-
boxylic acid (TCA) cycle and suppress oxidative phosphoryla-
tion, allowing cancer cells to avoid excessive production of
reactive oxygen species (ROS) and prevent mitochondria-driven
apoptosis (Cairns et al., 2011; Dang, 2012; Schulze and Harris,
2012). One of the critical gatekeepers controlling the flow of py-
ruvate to lactate in the cytosol or to acetyl-coenzyme A (CoA) in
mitochondria is pyruvate dehydrogenase (PDH) kinase (PDK).
PDK negatively regulates PDH, which catalyzes the conversion
of pyruvate to acetyl-CoA, thereby constraining the utilization
of pyruvate for oxidative metabolism while enhancing glycolysis
preferred by tumor cells.
In this study, we describe KDM4A as a coactivator of E2F1 and
report that the KDM4A-E2F complex regulates metabolism by
upregulating PDK1 and PDK3, thereby promoting the switch of
oxidative phosphorylation to glycolytic metabolism, offering pro-
liferative and survival advantages to prostate cancer cells.
RESULTS
KDM4A Addiction by Prostate Cancer Cells In Vitro and
Ex Vivo
Previously, we found that inhibition of KDM4A/4B by the small
molecule inhibitor NSC636819, or through knockdown by spe-
cific short hairpin RNA (shRNA) strongly inhibited the growth of
LNCaP prostate cancer cells (Chu et al., 2014). Here, we further
tested the growth of immortalized normal prostate epithelial
cells, RWPE-1, and two other cancer cell lines, CWR22Rv1
and C4-2B, transduced with control (pLKO.1) or KDM4A knock-
down constructs (shKDM4A). The result is consistent with our
previous finding showing that knockdown of KDM4A drastically
inhibited proliferation and induced apoptosis in the cancer cells,
while no significant differences were observed in the normal
RWPE-1 cell (Figures 1A–1D). In addition to RWPE-1, we tested
PNT2, another immortalized normal prostate epithelial cell and
found no significant effects on proliferation and survival when
knocking down KDM4A (Figure S1), suggesting that potential
addiction to KDM4A evolved in cancer cells. To determine the
significance of KDM4A in tumor growth, xenografts were estab-lished using control or shKDM4A-transduced CWR22Rv1 cells.
Similar to in vitro cell growth, the xenograft tumor formation
and growth derived from KDM4A-knockdown cells was signifi-
cantly inhibited (Figure 1E). Immunohistochemistry (IHC) also
showed lower expression of the proliferation marker Ki-67 in
shKDM4A xenograft tumors (Figure 1F). Together, these results
suggest that KDM4A is indispensable for prostate tumor growth
in vitro and ex vivo and is essential for the survival of prostate
cancer cells.
KDM4A’s Association with E2F1 and Coregulation of
Target Genes
To understand the mechanism underlying KDM4A-dependent
cell growth and survival, the gene expression profiles of
KDM4A-knockdown cells was determined by microarray anal-
ysis (GEO: GSE77928). A large set of genes involved in cell-cycle
regulation and cell division were altered in the shKDM4A cells
(Figure 2A). Many of these echoed the genes identified in
NSC636819-treated cells, including a subset of E2F1 targets
(Figure S2A) (Chu et al., 2014). Given that NSC636819 exhibited
the strongest inhibitory efficacy toward the KDM4 family,
compared to other demethylases tested (Figure S2B), the com-
mon genes identified upon KDM4A knockdown and inhibitor
treatment indicate that KDM4A is likely the major target of
NSC636819 and suggest that KDM4A regulates the expression
of E2F1 targets. Confirmed by qRT-PCR, downregulation of
the E2F1 target genes appeared to occur in an early-response
manner 2 days upon KDM4A knockdown, suggesting that they
are likely direct transcriptional targets of KDM4A (Figures 2B
and S2C). In CWR22Rv1-derived xenografts, the same set of
genes were also downregulated in shKDM4A tumors (Figure 2C),
confirming KDM4A-dependent cell-cycle gene regulation both
in vitro and ex vivo. To understand whether KDM4A and E2F1
share similar chromatin binding profiles, we surveyed pub-
lished chromatin immunoprecipitation (IP) sequencing (ChIP-
seq) datasets for KDM4A (GEO: GSM831035) and E2F1 (GEO:
GSM935366) and found an extensive intersection of KDM4A
and E2F1 chromatin binding sites (Figure 2D). Although the
ChIP-seq analyses were performed using different cell lines for
KDM4A and E2F1 (hESC [human embryonic stem cell] and
HeLa, respectively), the overlapped chromatin binding sites
strongly suggest that KDM4A and E2F1 share a large set of
common targets and that these two proteins may cooperatively
function in transcriptional regulation as a general mechanism
across different cell types.
Next, we determined whether KDM4A and E2F1 physically
interact with each other. When co-expressed in 293T cells, hem-
agglutinin (HA)-tagged E2F1 was co-precipitated with FLAG-
tagged KDM4A in the anti-FLAG immunoprecipitated complex
(Figure 3A). Importantly, the interaction of E2F1 and KDM4A
was further detected at the endogenous level in both LNCaP
and CWR22Rv1 cells, suggesting natural association between
these two proteins (Figure 3B). Using various truncates of
FLAG-KDM4A for co-immunoprecipitation, we mapped the ma-
jor E2F1 binding domain to amino acids 249–600 of KDM4A,
which covers part of the JmjC domain and its adjacent region
(Figure 3C). Reciprocally, in GST (glutathione S-transferase)
pull-down assays using purified GST-E2F1 fusion proteins andCell Reports 16, 3016–3027, September 13, 2016 3017
Figure 1. KDM4A Is Essential for Tumor Cell Proliferation
(A and B)MTT cell proliferation assay (A) and crystal violet staining (B) of normal immortalized RWPE-1 cell and prostate cancer cell lines LNCaP, CWR22Rv1, and
C4-2B, infected with lentivirus carrying control pLKO.1 or shKDM4A constructs. The cells were infected on day 0, andMTTwas added to detect viable cells every
2 days after infection. 8 days after lentiviral infection, the cells were fixed and stained by crystal violet. OD570, optical density at 570 nm.
(C) Caspase 3/7 activity of the lentiviral-infected cells was detected on day 6.
(D) 3 days after infection, the expression of KDM4A was examined by western blotting. c, control; sh1, shKDM4A-1; sh2, shKDM4A-2.
(E) CWR22Rv1 xenograft tumor growth. CWR22Rv1 cells were infected by lentivirus carrying pLKO.1 or shKDM4A for 2 days and then implanted subcutaneously
into nude mice. 10 days after implantation, the tumor volumes were measured for up to 3 weeks. Data are presented as mean ± SD, with the SD derived from ten
mice.
(F) Ki-67 and KDM4A immunohistochemistry staining of the tumor sections isolated from the xenografts.
All cell-culture-based data are presented as the average of nR 3 replicates ± SD. *p < 0.05; **p < 0.01.FLAG-KDM4A recombinant protein, the KDM4A binding site on
E2F1 was mapped to the leucine zipper and marked box dimer-
ization domain (Figure 3D). These results suggest that KDM4A
directly associates with E2F1 and coregulates a subset of com-
mon target genes.
KDM4A as E2F1 Coactivator
Next, we determined whether KDM4A and E2F1 are co-recruited
to the same target loci in prostate cancer cells. ChIP assays with
anti-E2F1 and anti-KDM4A antibodies demonstrated that these
proteins occupied the same promoter regions of CDK1 and
CCNE2 proximal to transcriptional start sites (TSSs) (Figure 4A).
Occupancies at distal regions were used as background con-
trols. The binding of KDM4A-E2F1 complex to target chromatin
was further evidenced by ChIP-reChIP assay using anti-KDM4A
to pull down the chromatin complex, followed by a second
precipitation with immunoglobulin G (IgG), anti-E2F1, or anti-
KDM4A antibodies (Figure 4B). In addition to CDK1 and
CCNE2, the chromatin occupancy of KDM4A was also detected
on other E2F1 target promoters, such as AURKB, CDC6,
CCNE1, and UBE2C (Figure S3A). Interestingly, the chromatin
binding of KDM4A and E2F1 on cell-cycle genes appeared in3018 Cell Reports 16, 3016–3027, September 13, 2016both a spatial and a temporal co-recruitment manner. After
release from cell-cycle arrest, KDM4A and E2F1 showed similar
patterns of chromatin occupancy along cell-cycle progression,
peaking at S phase in both LNCaP and HeLa cells (Figures 4C
and S3B). Using reporter constructs containing the CDK1 or
CCNE1 promoter, we next examined whether the presence of
KDM4A stimulates E2F1 transcriptional activity. While KDM4A
alone did not induce luciferase activity, overexpressing KDM4A
with E2F1 strongly enhanced E2F1 transcriptional activity on
the target promoters (Figure 4D). Remarkably, this enhancement
was not observed when overexpressing catalytic inactive
KDM4A(H188A), suggesting that the demethylase activity of
KDM4A is required for promoting E2F1 activity (Figure 4D).
This requirement was also evidenced by an elevated level of
H3K9me3 on the target promoters when knocking down
KDM4A, which further led to reduced enrichment of E2F1 and
RNA polymerase II (PolII) (Figure 4E). Suppressed recruitment
of E2F1 by NSC636819 treatment also indicated the importance
of demethylase activity (Figure S3C). While not dramatic, we
noted a slight reduction of E2F1 expression after KDM4A knock-
down in LNCaP and CWR22Rv1 cells that may also contribute to
the lower chromatin binding of E2F1 (Figure S3D). To understand
Figure 2. KDM4A Regulates Expression of E2F1 Target Genes
(A) DAVID functional annotation and pathway analysis of the genes that showed 2-fold alterations in KDM4A-knockdown LNCaP cells in microarray analysis. GOs
(Gene Ontologies) that showed statistically strong enrichment of alteration with low p values are listed. Bar graph and the numbers indicate gene counts of each
pathway. % of hits indicates the percentage of genes that are altered in each GO.
(B) Gene expression in LNCaP cells transduced with control or shKDM4A for 3 days was detected by qRT-PCR. The data are presented as the average of n = 3
replicates ± SD. The statistic of difference between shKDM4A and pLKO.1 is p < 0.01.
(C) qRT-PCR analysis of the gene expression in eight tumors isolated from CWR22Rv1-pLKO.1 and -shKDM4A xenografts. Color scheme indicates maximum
(Max) and minimum (Min) expression across the eight tumor specimens.
(D) Intersection of published KDM4A (GSM831035) and E2F1 (GSM935366) ChIP-seq binding sites examined in hESC and HeLa cells, respectively.whether E2F1 reciprocally modulates KDM4A recruitment, we
knocked down E2F1 and performed a KDM4A ChIP assay. Inter-
estingly, the binding of KDM4A was partially inhibited, suggest-
ing that E2F1 also contributes to the targeting and enrichment of
KDM4A (Figure S3E). Together, we showed that E2F1 influences
the enrichment of KDM4A, which, in turn, enhances E2F1 bind-
ing and promotes E2F1 transcriptional activity via the histone
demethylation activity.
KDM4A Regulation of PDKs
Among the altered genes identified in the microarray analysis,
downregulation of PDK3 (3-fold) drew our attention because of
the increasing appreciation of metabolism in cancer develop-
ment. PDK regulates the balance of glycolytic and mitochondrial
oxidative metabolism through PDH and plays a critical role in tu-
mor metabolism. In a panel of prostate cells, including the pri-
mary immortalized epithelial cells and several cancer cell lines,
qRT-PCR showed that PDK1 and PDK3 were generally overex-
pressed in the cancer cells, whereas PDK2 and PDK4 were ex-
pressed at significantly lower levels and did not show obvious
alteration in cancer cells, except for the high PDK4 in CWR22Rv1
cells (Figure S4A). In several clinical datasets, elevated levels of
PDK1 and PDK3 are also associated with advanced prostatecancer (Figure S4B), indicating their important roles in the cancer
development. Given that PDK4 was previously reported to be a
direct target of E2F1 (Hsieh et al., 2008), we asked whether the
KDM4A-E2F1 complex also directly regulates transcription of
PDK1 and PDK3 in prostate cancer cells. Based on the ENCODE
ChIP-seq data, all PDK family members appear to harbor E2F1
binding sites in their promoter regions (Figure 5A; PDK2 and
PDK4 not shown). In LNCaP cells, ChIP and ChIP-reChIP assays
demonstrated that E2F1 and KDM4A, indeed, bound to PDK1
and PDK3 promoters in the same complex (Figures 5B and
5C). As expected, when KDM4A was knocked down, the repres-
sive H3K9me3 mark was increased, and E2F1 binding was
impaired on these promoters (Figure 5D), which is also associ-
ated with reduced levels of PDK1 and PDK3 expression (Fig-
ure 5E). Remarkably, analyses of the expression data from clin-
ical datasets of the Sawyers (370 samples), TCGA (497 samples),
and Sueltman (95 samples) studies (mentioned in the Supple-
mental Information) showed a strong positive correlation be-
tween KDM4A and PDK1 or PDK3 (Figure S5A). The protein
expression in cultured normal and cancerous prostate cells, on
the other hand, also showed a general positive correlation be-
tween KDM4A and the PDKs (Figure S5B). Together, these re-
sults suggest that PDK1 and PDK3 are direct transcriptionalCell Reports 16, 3016–3027, September 13, 2016 3019
Figure 3. KDM4A Associates with E2F1
(A) Association of ectopically expressed KDM4A with E2F1. 293T cells were co-transfected with FLAG or FLAG-KDM4A and HA-E2F1 followed by IP using anti-
FLAG antibody. The co-immunoprecipitated E2F1 was detected by anti-HA antibody with immunoblotting (IB).
(B) Endogenous association of KDM4A and E2F1. LNCaP and CWR22Rv1 cell lysates were used for KDM4A IP, and the co-immunoprecipitated E2F1 was
detected by anti-E2F1 antibody. Mouse normal IgG was used as negative control.
(C) FLAG-KDM4A truncated proteins and HA-E2F1 were co-expressed in 293T cells for coIP as described earlier. Asterisks indicate positive binding.
(D) In vitro GST pull-down assay of recombinant GST-E2F1 fragments with purified FLAG-KDM4A protein. Asterisk indicates positive binding. DBD, DNA-binding
domain; LZ, leucine zipper; MB, marked box; TD, transactivation domain.targets of the KDM4A-E2F1 complex. Consistently, KDM4A-
dependent PDK1 and PDK3 expression was also observed in
CWR22Rv1 and C4-2B cells, as well as in the CWR22Rv1-
derived xenograft tumors (Figures S6A and S6B).
KDM4A-Dependent Metabolic Regulation
After the final step of glycolysis, pyruvate is converted to acetyl-
CoA by PDH to fuel the TCA cycle in mitochondria. By directly
phosphorylating PDH and inhibiting its activity, PDK tightly
modulates the carbon flow from glycolysis into mitochondrial
metabolism and cellular respiration. To further determine the
biological significance of KDM4A-dependent PDK1 and PDK3
regulation, we examined PDH activity in cells by knocking
down KDM4A, PDK1, or PDK3. Phenocopying the PDK-knock-
down cells, PDH activity was significantly elevated in KDM4A-
depleted cells compared to the control group (Figure 6A). The
upregulated PDH activity presumably accelerated the conver-
sion of pyruvate in mitochondria, thereby leading to decreased
lactate production and secretion (Figure 6B). These results
suggest a shift of glycolytic metabolism to mitochondrial
oxidation and respiration via activation of PDH complexes. In
agreement with this, the KDM4A-, PDK1-, and PDK3-knock-
down cells exhibited significantly lower extracellular acidification
rates (ECARs) (Figure 6C) and higher oxygen consumption rates
(OCRs) at both basal andmaximal levels, coupledwith increased
ATP synthesis capacity (Figure 6D), indicating reduced acidifica-
tion from glycolysis and elevated mitochondrial oxidative phos-
phorylation. As a consequence of enhanced respiration, these
cells displayed excessive ROS production in the mitochondria,
labeled by MitoSOX (Figure 6E). Consistent with the effects
observed in LNCaP, KDM4A knockdown in CWR22Rv1 cells3020 Cell Reports 16, 3016–3027, September 13, 2016also increased the cellular PDH activity and mitochondrial ROS
accumulation (Figures S6C and S6D). Moreover, pharmacolog-
ical inhibition of KDM4A by NSC636819 treatment also led to
similar metabolic phenotypes (Figures S7A–S7G). These data
collectively showed that KDM4A plays an important role in
modulating the cellular metabolic switch between glycolysis
and oxidative phosphorylation by controlling PDK1 and PDK3
expression. Given that knocking down these PDKs strongly in-
hibited cell proliferation (Figure 6F) and induced caspase-3/7
activation (Figure 6G), we suggest that the KDM4A-dependent
PDK1 and PDK3 expression and their high levels in prostate can-
cer cell play a critical role in tumor growth and survival.
To confirm that the KDM4A-mediated metabolic regulation is,
indeed, channeled through PDK1 and PDK3, we ectopically ex-
pressed these kinases in the KDM4A-knockdown cell by lentivi-
ral transduction. Compared to the empty vector control, expres-
sion of PDK1 and PDK3 is able to rescue the shKDM4A-induced
metabolic defects partially, but with statistical significance. The
rescued phenotypes included lower PDH activity, higher glycol-
ysis and lactate production, and decreased OCRs (Figures 7A–
7D). The accumulation of total and mitochondrial ROS in
shKDM4A cells was also reduced when overexpressing PDK1
or PDK3 (Figure 7F). This restoration suggests that PDK1 and
PDK3 are the effectors of KDM4A in modulating the glycolytic
and oxidative metabolism.
DISCUSSION
KDM4A is overexpressed in many cancer types, including pros-
tate, breast, lung, and colon cancers, and its expression is critical
for cell proliferation (Berry et al., 2012; Chu et al., 2014; Cloos
Figure 4. Chromatin Recruitment of KDM4A with E2F1 Enhances
E2F1 Transcriptional Activity
(A) ChIP analysis of KDM4A and E2F1 occupancy on CDK1 and CCNE2 pro-
moters in LNCaP cells using IgG, anti-KDM4A, or anti-E2F1 antibodies. ChIP
DNAs were analyzed by qPCR with primers that amplify genomic regions
either proximal (P) or distal (D) to TSSs for each gene.
(B) ChIP-reChIP assay of KDM4A and E2F1 binding. LNCaP chromatin was
used for the first ChIP with anti-KDM4A. The KDM4A-bound chromatin waset al., 2006; Kim et al., 2012; Li et al., 2011, 2012; Mallette and Ri-
chard, 2012).We previously reported that, by selectively inhibiting
KDM4A/4B with a small molecule inhibitor, the LNCaP prostate
cancer cells displayed drastic growth retardation and increased
apoptosis (Chu et al., 2014). Here, we showed that knockdown
of KDM4Awith specific shRNAs inhibited cell growth and induced
apoptosis in prostate cancer cells but not in immortalizedprostate
epithelial cells. These results suggest that the cancer cells may
have evolved addiction to higher level and pro-tumor properties
of KDM4A. Significantly, downregulation of KDM4A impaired tu-
mor formation in CWR22Rv1 xenografts. Given that the progres-
sion of prostate cancer into CRPC remains the biggest challenge
for intervention, our finding of the effective growth inhibition and
cell death induction achieved by KDM4A knockdown in the
castration-resistant CWR22Rv1 and C4-2B cells provides sup-
portive evidence for KDM4A as a potential therapeutic target in
advanced prostate cancer.
KDM4Awas first implicated in prostate cancer with its function
in AR signaling pathway (Shin and Janknecht, 2007). A recent
report showed that KDM4A drives prostate cancer development
via transcription factor EVT1 and the downstream target YAP1
expression (Kim et al., 2016). Here, we report that E2F1 is
another transcriptional factor regulated by KDM4A, and we
demonstrate an E2F1-KDM4A functional connection in the con-
trol of tumor growth. First, expression of a subset of E2F1 targets
involved in cell cycle, DNA replication, chromosome organiza-
tion, and chromosome segregation was significantly altered in
KDM4A-knockdown cells and in a xenograft model. Second,
KDM4A physically interacts with E2F1. Third, KDM4A and
E2F1 are co-recruited to the same targets and share significantly
overlapped chromatin binding sites. Fourth, overexpression of
KDM4A enhances E2F1 transcriptional activity in a demethylase
activity-dependent manner. Finally, knockdown of KDM4A re-
sults in elevated H3K9me3 and decreased occupancy of E2F1
on the target promoters. Reciprocally, E2F1 depletion influences
the enrichment of KDM4A on targets, indicating that E2F1 can
help KDM4A’s target recognition and occupancy. The binding
of KDM4A, in turn, alters the local chromatin status and further
enhances E2F1 binding. Our data not only provides mechanistic
evidence for KDM4A-dependent gene regulation through E2F1
but also echoes the finding of Black et al. (2010), which showseluted and subjected to reChIP using IgG, anti-E2F1, or anti-KDM4A, followed
by qPCR analysis of the target sites.
(C) KDM4A and E2F1 occupancy on the target promoters during cell-cycle
progression. LNCaP cells were arrested at G1/S transition by double thymidine
block and subsequently released to complete medium at 0 hr. Cells at the
indicated time points were harvested for KDM4A and E2F1 ChIP assays. The
protein levels and phospho-H3S10, indicating the stage of mitosis, are shown
in the western blots.
(D) CDK1 and CCNE1 promoter activities. The CDK1 and CCNE1 promoter-
luciferase constructs were co-expressed with empty HA or HA-E2F1, and
wild-type (wt) or inactive (H188A) KDM4A in PC3 cells. The luciferase activity
was measured 48 hr after transfection.
(E) Enrichment of E2F1, PolII, and H3K9me3 on the target promoters in control
and KDM4A-knockdown LNCaP cells. The level of H3K9me3 was normalized
by histone H3. The western blot shows KDM4A level.
All data are presented as the average of n = 3 replicates ± SD. *p < 0.05;
**p < 0.01.
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Figure 5. PDK1 and PDK3 Are Direct Targets of KDM4A and E2F1
(A) Schematic PDK1 and PDK3 promoters. Black bars indicate putative E2F
response elements and the consensus sequence. White bars indicate E2F1
binding sites identified in ENCODE ChIP-seq analysis. Gray bars indicate the
qPCR amplification sites proximal to the TSSs used in this study.
(B) ChIP-qPCR analysis of KDM4A and E2F1 occupancy on proximal (P) or
distal (D) regions of PDK1 and PDK3 promoters in LNCaP cells. The distal site
for PDK1 was designed at the intergenic region downstream of PDK1.
(C) ChIP-reChIP assay of KDM4A and E2F1 binding on the PDK1 and PDK3
promoters, as described in the Figure 4B legend.
(D) Enrichment of E2F1 andH3K9me3 onPDK1 andPDK3 promoters in control
and KDM4A-knockdown LNCaP cells. The H3K9me3 level was quantified as
described in the Figure 4E legend.
3022 Cell Reports 16, 3016–3027, September 13, 2016that, by regulating the level of H3K9me3 and subsequently atten-
uating chromatin binding for heterochromatin protein 1 gamma,
overexpression of KDM4A increases chromatin accessibility for
DNA replication machinery and facilitates S-phase progression.
The involvement of KDM4A in cell-cycle regulation is also sup-
ported by its counteracting partner, Suv39H1methyltransferase,
which dissociates from chromatin during S to G2-M transitions,
thereby promoting the KDM4A occupancy (Park et al., 2014).
Our results support the notion that concerted activities frommul-
tiple histone modifiers regulate the balance of active and repres-
sive histone marks on E2F-responsive promoters to fine-tune
gene expression and coordinate cell-cycle transition.
In addition to its function in cell cycle, we describe a role of
KDM4A-E2F1 in tumor metabolism. This resonates with a recent
report (Zhao et al., 2016), which links KDM4C to amino acidmeta-
bolism. We found that KDM4A-E2F1 is involved in glycolytic and
oxidative metabolic regulation by increasing PDK expression. As
a gatekeeping enzyme for the conversion of pyruvate into acetyl-
CoA inmitochondria, PDKplays a pivotal role in shifting cell meta-
bolism toward glycolysis to support the proliferative and survival
needs of tumor cells. Because of this distinct feature in cancer,
targeting PDK has been recognized as an effective anticancer
therapeutic strategy. Numerous pre-clinical studies have shown
that a small molecule inhibitor of PDK, dichloroacetate (DCA), is
effective in inhibiting proliferation of a wide range of cancers by
reversing the glycolytic phenotype, depolarizing mitochondria,
and inducing apoptosis (Bhat et al., 2015; Sutendra and Michela-
kis, 2013). Here, we provide evidence showing that PDK1 and
PDK3 are overexpressed in prostate cancer cells and that their
overexpression is associated with advanced cancers. Likewise,
knockdown of these PDKs drastically inhibited proliferation and
induced apoptosis with severe oxidative phenotypes in prostate
cancer cells. We showed that KDM4A induces transcription of
PDK1 and PDK3 by altering the chromatin status, thus enhancing
E2F1 transcriptional activity on these genes. Downregulation of
the PDKs by KDM4A inhibition shifted the metabolism toward
oxidative phosphorylation and caused excessive accumulation
of ROS that may contribute to the induction of apoptosis. More-
over, ectopic expression of PDK1 or PDK3 partially rescued the
shKDM4A-induced metabolic phenotypes, demonstrating that
the KDM4A-dependent metabolic regulation is, at least in part,
channeled through PDK1 and PDK3. The reasons that we do
not see full rescue could be due to two possibilities. First,
KDM4Amay participate in the modulation of other cellular factors
involved in metabolic regulation. Second, overexpressing PDK1
and PDK3 individually may not achieve the combined level of all
four members. Several pieces of evidence indicate that dysregu-
lation of PDK in cancer is contributed by oncogenes and tumor
suppressors such as HIF1a, c-Myc, p53, and Rb (Contractor
and Harris, 2012; Hsieh et al., 2008; Kim et al., 2007; Papandreou
et al., 2006). Together with our findings, the evidence collectively
suggests that tumor cells utilize multiple pathways, including(E) RNA and protein levels of KDM4A, PDK1, and PDK3 in pLKO.1 and
shKDM4A cells. LNCaP cells infected for 3 days were harvested for qRT-PCR
and western blotting.
All data are presented as the average of n = 3 replicates ± SD. *p < 0.05;
**p < 0.01.
Figure 6. Knockdown of KDM4A, PDK1, or
PDK3 Induces Mitochondrial Metabolism
(A and B) LNCaP cells were infected by lentivirus
carrying pLKO.1, shKDM4A, shPDK1, or shPDK3.
3 days after infection, the cells and cultured media
were harvested to measure cellular PDH activity (A)
and lactate secretion (B). The PDH activity was
normalized by protein concentration of the cell
lysates.
(C and D) The cellular ECAR andOCRweremeasured
on day 3 after lentiviral infection.
(E) Mitochondrial ROS was detected by MitoSOX
fluorescence dye 4 days after transduction. Images
from randomly selected fields were taken. Scale bar,
50 mm.
(F and G) Cell growth and caspase-3/7 activity in
shPDK1 and shPDK3 cells were examined as
described in the legends for Figures 1A, 1B, and 1D.
PDK1 and PDK3 expression is shown in the western
blots.
All data are presented as the average of n = 3 repli-
cates ± SD. *p < 0.05; **p < 0.01.epigenetic modification to ensure the activation of the PDH com-
plex during cancer progression.
Cell proliferation requires coordination betweenmetabolic sig-
nals and cell-cycle machinery. Although the mechanism is notCell Repofully understood, increasing evidence indi-
cates that cell-cycle regulators such as
E2F1, Rb, Cdk4, and cyclin D possess
dual roles in both cell-cycle and metabolic
control (Fajas, 2013). The cooperative
role of KDM4A and E2F1 described in this
study provides the first evidence of an
epigenetic link for cell-cycle and metabolic
regulation.
Although KDM4A was reported to sup-
press gene expression (Gray et al., 2005;
Zhang et al., 2005), we found that
KDM4A plays primarily an activating role
for E2F1, as did several other reports,
which documented KDM4A as an acti-
vator (Berry et al., 2012; Shin and Jan-
knecht, 2007). It seems that KDM4A’s
role in repression or activation depends
on its binding partners as well as the
requirement for demethylation activities.
Although it is not clear whether KDM4A-
mediated repression requires its demethy-
lase activity, our work as well as that of
others (Berry et al., 2012; Shin and Jan-
knecht, 2007) all indicate the importance
of H3K9me3 removal in the activation.
Further study will be needed to under-
stand how KDM4A coordinates both acti-
vation and repression on E2F1 targets.
As an enzyme, KDM4A offers itself as a
potentially ‘‘druggable’’ target for tumor
metabolic reprogramming. Given thatsome cancer cells lack the expression of DCA transporter
SLC5A8 and, hence, require higher doses of DCA to achieve
antitumor effects (Babu et al., 2011), KDM4A may serve as
an effective alternative for metabolic targeting.rts 16, 3016–3027, September 13, 2016 3023
Figure 7. Ectopic Expression of PDK1 and PDK3 Rescues the KDM4A Metabolic Phenotypes
Lentivirus carrying PDK1- or PDK3-overexpression constructs were used to infect LNCaP cells together with the shKDM4A virus.
(A–D) PDH activity (A), lactate production (B), ECAR (C), and OCR (D) were measured as described in Figure 6 3 days after infection.
(E) Total cellular ROS was labeled by CM-H2DCFDA.
(F) Mitochondrial ROS was detected by MitoSOX fluorescence dye as described in the Figure 6E legend. Scale bar, 50 mm.
(G) KDM4A, PDK1, and PDK3 protein levels were examined 3 days after infection.
All data are presented as the average of n = 3 replicates ± SD. *p < 0.05; **p < 0.01.In summary, we uncovered a KDM4A-E2F1 connection
and described KDM4A-dependent transcriptional regulation of
PDK1 and PDK3 in promoting tumor glycolytic switch in prostate
cancer cells. This finding sheds light on the role of epigenetic
regulators in tumor metabolism that may be exploited
therapeutically.
EXPERIMENTAL PROCEDURES
Cell Culture
RWPE-1, LNCaP, CWR22Rv1, PC3, and HEK293T cells were purchased from
ATCC and cultured according to the instructions provided. LNCaP-derived
C4-2 cells (Thalmann et al., 1994) were cultured in RPMI 1640medium supple-3024 Cell Reports 16, 3016–3027, September 13, 2016mented with 10% fetal bovine serum (FBS). Synchronization of LNCaP cells at
the G1/S phase was induced by double-thymidine block: thymidine (2 mM)
treatment for 18 hr, followed by wash and release in complete medium for
9 hr and then 16 hr of thymidine (2 mM) treatment.
Plasmids and Reagents
pLKO.1-shKDM4A (clone IDs: TRCN0000013493, TRCN0000234910), pLKO.1-
shPDK1 (TRCN0000006261), and pLKO.1-shPDK3 (TRCN0000379916) plas-
mids were obtained from the RNAi Consortium (TRC) library. pDONR223-
PDK1 (Addgene plasmid #23804) and pDONR223-PDK3 (Addgene plasmid
#23556) were gifts from William Hahn and David Root, distributed by Addgene.
The PDK1 and PDK3 cDNAs were amplified and cloned into pLenti4 vector
(Invitrogen), modified with the insertion of a CpoI cloning site. All lentivirus
was produced as described by Chu et al. (2014). HA-E2F1, CDK1-luciferase,
and CCNE1-luciferase plasmids are as described by Revenko et al. (2010).
KDM4A was cloned into pcDNA3-FLAG vector and recombinant baculovirus
transfer vector pFAST-BAC (Invitrogen). The full-length and various truncated
E2F1 cells were cloned into pGEX vector for GST-fusion protein construction.
Cell Proliferation and Caspase Activity
Cell proliferation was measured and detected with the MTT Cell Proliferation
Kit I (Roche) and crystal violet staining. Cells were seeded in triplicate in 48-
well plates 1 day prior to lentivirus infection (day 0), followed by the MTT assay
performed on days 0, 2, 4, 6, and 8 according to the manufacturer’s instruc-
tions. 50,000 cells were seeded in 12-well plates 1 day before lentivirus infec-
tion. 8 days after infection, the cells were fixed by methanol and stained by
0.5% crystal violet to visualize the cell expansion. Cellular caspase activity
was measured with the Caspase-Glo 3/7 Assay System (Promega) according
the manufacturer’s instructions.
Xenograft
CWR22Rv1 cells were infected by pLKO.1 or shKDM4A lentivirus for 48 hr. 3
million infected cells were implanted subcutaneously into ten nude mice for
each group. 10 days after implantation, the tumor volume wasmeasured every
2–3 days for 3 weeks. The tumor tissues were harvested and immediately
frozen in liquid nitrogen for RNA isolation or fixed in formalin for paraffin block
preparation. The animal study was performed according to the protocols
approved by the Institutional Animal Care and Use Committee of the University
of California, Davis (UC Davis). The formalin-fixed tissues were processed in
the UC Davis Cancer Center Biorepository Core for paraffin embedding,
sectioning, and IHC staining. Anti-JMJD2A (NeuroMab) antibody was used
for KDM4A IHC staining.
qPCR
RNeasy Plus kits (QIAGEN) were used to isolate total RNA. cDNA was synthe-
sized using SuperScript III First-Strand Synthesis reagents (Invitrogen). The
amount of cDNA was then quantified by the Bio-Rad CFX Real-Time PCR
detection system using SYBR Green SuperMix (Fermentas) and the primers
listed in Table S1. All samples were tested in triplicate, and the expression
levels were normalized against actin mRNA, GAPDH mRNA, and 18S rRNA.
Immunoprecipitation and Western Blotting
To obtain total lysates, cells were lysed in RIPA buffer (50 mM Tris [pH 8.0],
150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.5% SDS, protease inhib-
itors) on ice, followed by 10 min of sonication by Bioruptor. For IP, cells were
lysed with buffer containing Tris-HCl (50 mM [pH 8.0]), NaCl (150 mM), Triton
X-100 (0.5%), glycerol (10%), EDTA (1 mM), and protease inhibitors for 15 min
on ice. The lysates were then incubated with Flag-M2 agarose (Sigma-Aldrich)
or anti-JMJD2A (NeuroMab) at 4C overnight. The precipitated protein com-
plexes were washed four times the next day. Proteins were resolved in SDS-
PAGE for western blotting. Western blot images were taken with the Fluo-
rChem E system and analyzed with AlphaView SA software. Antibodies used
include: KDM4A (NeuroMab), Flag-M2 and b-actin (Sigma-Aldrich), HA (Cova-
nce), cyclin B1 and E2F1 (Santa Cruz), p-H3S10 (Millipore), and PDK1 and
PDK3 (Abcam). GST antibody was purified from rabbit antiserum generated
against a GST-tagged antigen.
Recombinant Protein Purification and GST Pull-Down Assay
GST and GST-E2F1 truncated proteins were expressed in E. coli strain BL21.
The bacteria was lysed by standard procedure, followed by incubation with
Glutathione-Sepharose beads (Pharmacia), and by washes and elution in
50 mM Tris- HCl (pH 8.0), 400 mM NaCl, 1 mM DTT, 1% Triton X-100, and
20 mM glutathione. FLAG-tagged KDM4A was purified from recombinant ba-
culovirus-infected Sf9 cells with the procedure described previously (Izumiya
et al., 2007). The purified recombinant GST-E2F1 and FLAG-KDM4A proteins
were incubated at 4C for 4 hr, followed by washes and western blotting
analysis.
ChIP and ChIP-reChIP
ChIP was performed following the UC Davis Genome Center ChIP protocol.
Briefly, cells were crosslinked by formaldehyde (1%). The crosslinked chro-matin was sonicated to fragment DNA to 200–500 bp. The lysate was pre-
cleared by protein A/G agarose and subsequently incubated with specific an-
tibodies—mouse IgG (Millipore), KDM4A (Bethyl), E2F1 (Millipore), H3 and
H3K9me3 (Abcam), and PolII (Genetex)—overnight at 4C. The ChIP com-
plexes were washed and eluted in 50 mM NaHCO3 and 1% SDS, followed
by overnight reverse crosslinking. For reChIP, KDM4A-bound chromatin
was eluted in buffer containing 50 mM NaHCO3, 1% SDS, 10 mM DTT. The
eluted ChIP complex was diluted 403 with ChIP IP buffer and incubated
with IgG, anti-E2F1, or anti-KDM4A overnight at 4C for a second ChIP.
The recovered DNAs from ChIP and ChIP-reChIP were analyzed by qPCR
using the primers listed in Table S2. For the published ChIP-seq dataset
analysis, the BED files of H1 hESCs-JMJD2A ChIP-seq (GSM831035) and
HeLa-S3_HA-E2F1_std ChIP-seq (GSM935366) were downloaded. Overlap-
ping peaks in each BED file were merged using the BEDTools ‘‘merge’’ com-
mand. In the JMJD2A dataset, 21,418 peaks weremerged into 18,033 peaks,
and in the E2F1 dataset, the number of peaks remained unchanged (5,153).
The merged BED files were then intersected with each other using the BED-
Tools ‘‘intersect’’ command.
Luciferase Assay
PC3 cells were seeded in 24-well plates 1 day prior to transfection. Cells
were co-transfected with empty FLAG vector, FLAG-KDM4A, or FLAG-
KDM4A(H188A) with HA or HA-E2F1, together with CDK1-luc or CCNE1-luc
plasmid. pRL-SV40 Renilla luciferase plasmid was used as transfection con-
trol. The luciferase activity was detected using the Dual-Luciferase Assay Kit
(Promega). All samples were tested in triplicate, and the luciferase relative light
units (RLUs) were normalized against the Renilla values.
Microarray
Global expression analysis was performed in LNCaP cells transduced with
shKDM4A or pLKO.1 for 3 days (GEO: GSE77928). Microarray analysis was
performed by the UC Davis Comprehensive Cancer Center Gene Expression
Resource, using Affymetrix Human Genome U133A Gene Chip arrays, which
permits expression analysis of the entire GenBank RefSeq database. Subse-
quent data analysis was done by GeneSpring (Agilent Technologies) and
DAVID Bioinformatics Resources.
Metabolic Assays and Mitochondrial ROS Detection
Cell culture media and cell pellets were harvested 3 days after lentiviral de-
livery of pLKO.1 or knockdown constructs. The cellular PDH activity and
lactate concentration in cultured media were measured using commercial
kits (BioVision) following the manufacturer’s instructions. All samples were
tested in triplicate. Mitochondrial superoxide was detected by MitoSOX
fluorescent indicator (Invitrogen). Briefly, cells were seeded on coverglass
in six-well plates before being subjected to lentivirus infection. 4 days after
transduction, cells were washed with PBS and Hank’s balanced salt solution
(HBSS), followed by incubation with MitoSOX (2.5 mM) for 30 min at 37C in
dark. The stained cells were washed, paraformaldehyde fixed, permeabi-
lized, and stained with DAPI to label nuclei. The cells were visualized by
confocal fluorescence microscopy (Zeiss LSM710). In each experiment, im-
ages of equal stacks of confocal sections were taken, and random fields of
view were selected. The Z-section images were processed by maximal pro-
jection using ImageJ. Cellular ROSwas labeled by 20,70-dichlorodihydrofluor-
escein diacetate (CM-H2DCFDA, Invitrogen) following the procedure
described by Eruslanov and Kusmartsev (2010). In brief, equal amounts of
cells were labeled with CM-H2DCFDA (10 mM) for 45 min and washed by
HBSS. The fluorescent signal was detected at excitation/emission = 485/
535 nm.
OCR and ECAR
Cellular mitochondrial function was determined using the Seahorse Biosci-
ence XF24 Extracellular Flux Analyzer according to manufacturer’s instruc-
tions. Cells were seeded in Seahorse plates and incubated overnight
before infection with lentivirus carrying pLKO.1 or knockdown constructs for
3 days. XF Cell Mito Stress and Glycolysis Stress test kits were used following
the manufacturer’s protocol.Cell Reports 16, 3016–3027, September 13, 2016 3025
Statistical Analysis
Experiments were performed in triplicate. Statistical analysis of the differences
between two groups was determined by two-tailed Student’s t test. p values
less than 0.05 were considered to be significant.
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